Alliances
Gilead and EVOQ Therapeutics announced a partnership to develop immunotherapies for rheumatoid arthritis and lupus.
Eli Lilly and ProQR Therapeutics expand their RNA-editing collaboration.
Merck entered into a license and collaboration agreement with Chinese company Kelun-Biotech to develop seven antibody-drug conjugates candidates against oncology targets.
Mergers and acquisitions are expected to be a key theme in the pharmaceutical industry in 2023.
Jazz Pharmaceuticals exercised its option on Zymeworks’ promising anti-cancer agent.
Sanofi and Innate Pharma expand their longtime collaboration by licensing up to three NK cells engager programs in cancer immunotherapy valued at more than $1.4 billion.
Lilly digs deeper into metabolic diseases via GPCR partnership with Sosei.
AbbVie and AbCellera inked an antibody discovery deal to develop candidates for up to five targets in several indications.
Kymera and Sanofi shared positive results for an IRAK4 degrader for hidradenitis suppurativa and atopic dermatitis.
See inside for BioSpace’s compilation of the five biggest M&A deals of 2022.
PRESS RELEASES